Compare Amgen, Inc. (AMGN) vs Bitdeer Technologies Group (BTDR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Bitdeer Technologies Group — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Bitdeer Technologies Group trades at $12.98 (market cap $3.23B). The key difference: Amgen, Inc. is far larger — about 60.7× Bitdeer Technologies Group's market cap, and Amgen, Inc. pays a 2.77% dividend while Bitdeer Technologies Group pays none. Which is the better fit depends on your goals.
| AMGN | BTDR | |
|---|---|---|
Market Cap | $196.12B | $3.23B |
Sector | Health | Technology |
52-Week High | $388.16 | $25.90 |
52-Week Low | $271.18 | $7.28 |
Enterprise Value | $241.41B | $5.00B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
BTDR trades at $13.29, down 7.26% in the last 24 hours, with a bearish technical signal and recent earnings misses. The company reported revenue growth to $620.25 million in 2025 but a net income margin of -26.96% in 2026, indicating profitability challenges. Positive developments include expansion into AI cloud infrastructure and new facility openings, yet negative cash flow from operations persists.
The outlook is mixed: strong analyst buy consensus (81.82%) and a $23.40 price target suggest upside, but operational losses and Bitcoin market volatility pose significant risks. Investment opportunity lies in AI infrastructure growth, while execution and sector headwinds require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Bitdeer Technologies Group
Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.
Read more on BTDR →
